NervGen Pharma Corp.

Recent News

  • NervGen Pharma Grants Stock Options

    Vancouver, British Columbia--(Newsfile Corp. - September 14, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 550,000 incentive stock options to Directors exercisable at a price of $2.10 per share for a period of five years with vesting that is either time or performance based. All options have been granted in accordance...

    2021-09-14 7:03 PM EDT
  • NervGen Pharma Presenting at the H.C. Wainwright 23rd Annual Global Investment Conference

    Vancouver, British Columbia--(Newsfile Corp. - September 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.The presentation will be available via webcast on demand starting on Monday, September 13, 2021, at 7:00 a.m. ET using the following link: https://journey.ct.events/view/042230bf-93b7-4555-984f-43a642d5735c.Paul Brennan,...

    2021-09-12 4:45 PM EDT
  • NervGen Pharma Announces Results of Annual General Meeting of Shareholders

    Vancouver, British Columbia--(Newsfile Corp. - September 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announces the results of its Annual General Meeting of Shareholders ("AGM") held on September 9, 2021. "We are very pleased to welcome Krista McKerracher and Glenn Ives to our Board of Directors as they are ideally suited to help NervGen as we...

    2021-09-10 8:30 AM EDT
  • NervGen Pharma Provides an Operational Update on Its Ongoing Phase 1 Clinical Trial and Reports Second Quarter 2021 Results

    Vancouver, British Columbia--(Newsfile Corp. - August 19, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an update on its Phase I clinical trial and is reporting its financial results for the second quarter ended June 30, 2021."The second quarter of 2021 was pivotal for NervGen as we started our Phase 1 clinical trial with NVG-291,"...

    2021-08-19 8:30 AM EDT
  • NervGen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer's Disease

    Vancouver, British Columbia--(Newsfile Corp. - August 9, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen's lead compound, NVG-291, in validated animal models of Alzheimer's disease."We are very happy to be collaborating with Massachusetts General...

    2021-08-09 8:30 AM EDT
  • NervGen Pharma Corp. Closes Non-Brokered Private Placement

    NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, is pleased to announce that it has closed a non-brokered private placement (the "Private Placement") of 1,511,636 units of the Company at a price of CAD$1.55 per unit, for aggregate gross...

    2021-08-05 8:30 AM EDT
  • NervGen Pharma Grants Stock Options

    Vancouver, British Columbia--(Newsfile Corp. - July 16, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 125,000 incentive stock options to existing consultants providing investor relations services, 25,000 of which are exercisable at a price of $1.75 per share and 100,000 of which are exercisable at $2.00 per share for a period...

    2021-07-16 7:52 PM EDT
  • NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board

    Vancouver, British Columbia--(Newsfile Corp. - July 15, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the formation of its Multiple Sclerosis (MS) Clinical Advisory Board comprised of six world-class scientific and clinical researchers in the field of multiple sclerosis: Drs. Jack Antel, Peter Calabresi, Jeremy Chataway, Jeffrey Cohen, Robert Naismith and Anneke van der Walt. This...

    2021-07-15 8:30 AM EDT